Skip to content

Study · Non-randomized trial · n = 42 · 2013

2 results

Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective.

Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Nakamura J, Ishikawa T, Miyagi M and 10 more

Show all authors

Kamoda H, Suzuki M, Kubota G, Sakuma Y, Oikawa Y, Inage K, Sainoh T, Takaso M, Toyone T, Takahashi K

Spine1 Apr 2013Cited by 219 (Europe PMC)

PMID23354115 (opens in a new tab)DOI10.1097/brs.0b013e31828826dd (opens in a new tab)PepBankPUB-23354115
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis after lumbar fusion, teriparatide reduced pedicle screw loosening compared with no osteoporosis medication.

    In plain wordsIn women with osteoporosis after lumbar fusion, teriparatide reduced screw loosening compared with no osteoporosis medication.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreasePedicle screw loosening
    Study

    n = 42

    Comparator
    No osteoporosis medication
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneousAs given in this study (human).

    Measurements

    Screw loosening incidence
    7 to 13%
    teriparatide
    Screw loosening incidence
    15 to 25%
    control

    Source sentences

    Summary
    At 12-month follow-up, the incidence of PS loosening was 7% to 13% in the teriparatide group, 13% to 26% in the risedronate group, and 15% to 25% in the control group.
    3 context sentences
    Summary · context
    The incidence of PS loosening in the teriparatide group was significantly lower than that in the risedronate or the control group (P < 0.05).
    Summary · context
    Sixty-two women with osteoporosis diagnosed with degenerative spondylolisthesis were divided into 3 groups: a teriparatide group (daily subcutaneous injection of 20 μg of teriparatide, n = 20), a bisphosphonate group (daily oral administration 2.5 mg of risedronate, n = 20), and a control group (wit…
    Summary · context
    All patients underwent decompression and 1- or 2-level instrumented posterolateral fusion with a local bone graft.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with osteoporosis after lumbar fusion, teriparatide reduced pedicle screw loosening compared with risedronate at follow-up.

    In plain wordsIn women with osteoporosis after lumbar fusion, teriparatide reduced screw loosening compared with risedronate.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreasePedicle screw loosening
    Study

    n = 40

    Comparator
    Risedronate
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg daily · subcutaneousAs given in this study (human).

    Measurements

    Screw loosening incidence
    7 to 13%
    teriparatide
    Screw loosening incidence
    13 to 26%
    risedronate

    Source sentences

    Summary
    At 12-month follow-up, the incidence of PS loosening was 7% to 13% in the teriparatide group, 13% to 26% in the risedronate group, and 15% to 25% in the control group.
    3 context sentences
    Summary · context
    The incidence of PS loosening in the teriparatide group was significantly lower than that in the risedronate or the control group (P < 0.05).
    Summary · context
    Sixty-two women with osteoporosis diagnosed with degenerative spondylolisthesis were divided into 3 groups: a teriparatide group (daily subcutaneous injection of 20 μg of teriparatide, n = 20), a bisphosphonate group (daily oral administration 2.5 mg of risedronate, n = 20), and a control group (wit…
    Summary · context
    All patients underwent decompression and 1- or 2-level instrumented posterolateral fusion with a local bone graft.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.